• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较桂利嗪和茶苯海明固定低剂量联合与倍他司汀治疗前庭神经炎的疗效:一项随机、双盲、非劣效性研究。

Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study.

机构信息

Department of Otorhinolaryngology, University of Innsbruck, Innsbruck, Austria.

出版信息

Clin Drug Investig. 2012 Jun 1;32(6):387-99. doi: 10.2165/11632410-000000000-00000.

DOI:10.2165/11632410-000000000-00000
PMID:22506537
Abstract

BACKGROUND

Vestibular neuritis (VN) is a strongly disabling disease of the peripheral vestibular system. Rapid and effective relief of symptoms is important to allow patients to promptly return to normal physical activity.

OBJECTIVE

The aim of this prospective, randomized, double-blind study was to evaluate the efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate in unilateral VN in comparison with betahistine in terms of improvement of vertigo and concomitant symptoms, and performance in neurotological testing.

METHODS

Sixty-two patients were randomized to receive either cinnarizine 20 mg/dimenhydrinate 40 mg as a fixed combination or betahistine 12 mg, each three times daily for 4 weeks. Vertigo and concomitant symptoms, activities of daily living (ADL), posturography and a battery of vestibulo-ocular tests, registered by electronystagmography including spontaneous nystagmus, bithermal caloric and rotatory test, among others, were assessed at baseline (t(0)), after 1 week (t(1w)) and after 4 weeks (t(4w)). The primary endpoint was the Mean Vertigo Score (MVS) at t(1w), a composite of 12 individual scores for unprovoked and provoked vertigo, each assessed using a 10 cm visual analogue scale (VAS). Non-inferiority of the fixed combination versus betahistine would be assumed if the two-sided 95% confidence intervals (CIs) for between-group differences in MVS lay entirely below the non-inferiority margin of 1.25 (12.5% of VAS range).

RESULTS

The fixed combination led to significantly greater improvements in MVS than betahistine both at t(1w) (primary endpoint) and at t(4w) (95% CI for the difference in baseline-adjusted means -0.95, -0.64 at t(1w), -0.77, -0.44 at t(4w); p < 0.001). Vegetative symptoms and ADL also improved significantly more under the fixed combination than under betahistine at t(1w) (p < 0.001, each parameter) and t(4w) (p < 0.001 and p < 0.01, respectively), both showing a nearly complete remission at t(4w). In the two groups, pathological posturography and electronystagmography parameters normalized during the 4-week treatment. The fixed combination group showed an earlier recovery of spontaneous nystagmus than the betahistine group (t(1w), p < 0.001) and slightly higher improvements in asymmetry of rotation-induced nystagmus at t(1w) and t(4w) (p = 0.041, each time point). No significant differences were found between the treatments in abatement of spontaneous nystagmus at t(4w) and decrease of caloric lateralization or improvement of equilibrium (sensory organization test [SOT], conditions 5/6) at t(1w) and t(4w). No patient reported any adverse event.

CONCLUSION

The results showed that the fixed low-dose combination of cinnarizine and dimenhydrinate is an effective and well tolerated option for symptomatic treatment in unilateral VN. The fixed combination led to significant improvements in vertigo and ADL within the first week, and to a nearly complete recovery after 4 weeks. Neurotological testing revealed no signs of a possible detrimental influence of the 4-week treatment with the fixed combination compared with betahistine in terms of recovery of caloric responsiveness and abatement of rotation-induced nystagmus.

摘要

背景

前庭神经炎(VN)是一种强烈致残的外周前庭系统疾病。快速有效地缓解症状对于患者尽快恢复正常的身体活动非常重要。

目的

本前瞻性、随机、双盲研究旨在评估与倍他司汀相比,固定低剂量桂利嗪和茶苯海明联合治疗单侧 VN 在改善眩晕和伴随症状方面的疗效,以及在神经耳科学测试中的表现。

方法

62 名患者随机分为接受桂利嗪 20mg/茶苯海明 40mg 固定联合治疗或倍他司汀 12mg,每日三次,持续 4 周。在基线(t(0))、第 1 周(t(1w))和第 4 周(t(4w))评估眩晕和伴随症状、日常生活活动(ADL)、姿势描记术和一系列前庭眼动测试,包括自发性眼震、双温测和旋转试验等,通过眼震电图记录。主要终点是 t(1w)时的平均眩晕评分(MVS),这是未经激发和激发性眩晕的 12 个个体评分的组合,每个评分均使用 10cm 视觉模拟量表(VAS)评估。如果双侧 95%置信区间(CI)落在 1.25(VAS 范围的 12.5%)以下,则假设固定联合与倍他司汀之间的组间差异的非劣效性。

结果

与倍他司汀相比,固定联合在 t(1w)(主要终点)和 t(4w)(基线调整均值的差异的 95%CI-0.95,-0.64 在 t(1w),-0.77,-0.44 在 t(4w);p<0.001)时均能显著改善 MVS。与倍他司汀相比,固定联合在 t(1w)(p<0.001,每个参数)和 t(4w)(p<0.001 和 p<0.01,分别)时也能显著改善植物性症状和 ADL,两组在 t(4w)时均显示出几乎完全缓解。在两组中,病理性姿势描记术和眼震电图参数在 4 周治疗期间正常化。与倍他司汀组相比,固定联合组的自发性眼震恢复更快(t(1w),p<0.001),并且在 t(1w)和 t(4w)时旋转诱发眼震的不对称性改善稍高(p=0.041,每次)。在 t(4w)时自发眼震的减轻和热量侧化的减少或平衡(感觉组织测试[SOT],条件 5/6)的改善方面,治疗之间未发现显著差异在 t(1w)和 t(4w)时。没有患者报告任何不良反应。

结论

结果表明,桂利嗪和茶苯海明的固定低剂量联合是单侧 VN 症状治疗的有效且耐受良好的选择。固定联合在第一周内显著改善了眩晕和 ADL,在四周后几乎完全恢复。神经耳科学测试显示,与倍他司汀相比,在恢复热量反应性和减轻旋转诱发眼震方面,四周的固定联合治疗没有迹象表明可能对治疗产生不利影响。

相似文献

1
Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study.比较桂利嗪和茶苯海明固定低剂量联合与倍他司汀治疗前庭神经炎的疗效:一项随机、双盲、非劣效性研究。
Clin Drug Investig. 2012 Jun 1;32(6):387-99. doi: 10.2165/11632410-000000000-00000.
2
Comparison of cinnarizine/dimenhydrinate fixed combination with the respective monotherapies for vertigo of various origins: a randomized, double-blind, active-controlled, multicentre study.比较桂利嗪/盐酸苯海拉明固定剂量复方与相应单药治疗各种来源眩晕的疗效:一项随机、双盲、阳性对照、多中心研究。
Clin Drug Investig. 2011;31(6):371-83. doi: 10.2165/11588920-000000000-00000.
3
Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferiority Clinical Trial.西尼必利嗪 20 毫克和茶苯海明 40 毫克固定组合与双氢盐酸倍他司汀 16 毫克治疗外周性前庭眩晕患者的疗效和安全性:一项前瞻性、多国、多中心、双盲、随机、非劣效性临床试验。
Clin Drug Investig. 2019 Nov;39(11):1045-1056. doi: 10.1007/s40261-019-00858-6.
4
Efficacy and tolerability of a fixed low-dose combination of cinnarizine and dimenhydrinate in the treatment of vertigo: a 4-week, randomized, double-blind, active- and placebo-controlled, parallel-group, outpatient study.桂利嗪和茶苯海明固定低剂量组合治疗眩晕的疗效和耐受性:一项为期4周的随机、双盲、活性药物和安慰剂对照、平行组门诊研究。
Clin Ther. 2007 Jan;29(1):84-98. doi: 10.1016/j.clinthera.2007.01.010.
5
A fixed combination of cinnarizine/dimenhydrinate for the treatment of patients with acute vertigo due to vestibular disorders : a randomized, reference-controlled clinical study.桂利嗪/茶苯海明固定组合治疗前庭障碍所致急性眩晕患者:一项随机、对照临床研究
Clin Drug Investig. 2008;28(2):89-99. doi: 10.2165/00044011-200828020-00003.
6
Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Ménière's disease: a randomized, double-blind, parallel group clinical study.桂利嗪与茶苯海明固定组合对比甲磺酸倍他司汀治疗梅尼埃病:一项随机、双盲、平行组临床研究
Int Tinnitus J. 2002;8(2):115-23.
7
Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials.西尼必利嗪 20 毫克与茶苯海明 40 毫克固定剂量组合治疗前庭性眩晕患者的疗效和安全性:一项随机、双盲、对照临床试验的个体患者数据荟萃分析。
Clin Drug Investig. 2022 Sep;42(9):705-720. doi: 10.1007/s40261-022-01184-0. Epub 2022 Jul 21.
8
Treatment of vertebrobasilar insufficiency--associated vertigo with a fixed combination of cinnarizine and dimenhydrinate.用桂利嗪和茶苯海明固定复方治疗椎基底动脉供血不足相关性眩晕。
Int Tinnitus J. 2008;14(1):57-67.
9
Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: a double-blind, randomized, parallel-group clinical study.桂利嗪与茶苯海明固定复方治疗急性单侧前庭功能丧失所致眩晕:一项双盲、随机、平行组临床研究。
Clin Ther. 2004 Jun;26(6):866-77. doi: 10.1016/s0149-2918(04)90130-0.
10
Influence of 3 antivertiginous medications on the vigilance of healthy volunteers.三种抗眩晕药物对健康志愿者警觉性的影响。
Int J Clin Pharmacol Ther. 2003 Apr;41(4):171-81. doi: 10.5414/cpp41171.

引用本文的文献

1
[Otorhinolaryngologic diagnostics and treatment of vertigo syndromes].[眩晕综合征的耳鼻咽喉科诊断与治疗]
HNO. 2025 Apr 7. doi: 10.1007/s00106-025-01592-6.
2
Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials.西尼必利嗪 20 毫克与茶苯海明 40 毫克固定剂量组合治疗前庭性眩晕患者的疗效和安全性:一项随机、双盲、对照临床试验的个体患者数据荟萃分析。
Clin Drug Investig. 2022 Sep;42(9):705-720. doi: 10.1007/s40261-022-01184-0. Epub 2022 Jul 21.
3

本文引用的文献

1
Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis).用于治疗特发性急性前庭功能障碍(前庭神经炎)的皮质类固醇
Cochrane Database Syst Rev. 2011 May 11(5):CD008607. doi: 10.1002/14651858.CD008607.pub2.
2
No effects of anti-motion sickness drugs on vestibular evoked myogenic potentials outcome parameters.抗晕动病药物对前庭诱发肌源性电位结果参数无影响。
Otol Neurotol. 2011 Apr;32(3):497-503. doi: 10.1097/MAO.0b013e31820d94d0.
3
Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss.
Experimentally designed chromatographic method for the simultaneous analysis of dimenhydrinate, cinnarizine and their toxic impurities.
用于同时分析茶苯海明、桂利嗪及其有毒杂质的实验设计色谱方法。
RSC Adv. 2021 Jan 5;11(3):1450-1460. doi: 10.1039/d0ra09585k. eCollection 2021 Jan 4.
4
Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.前庭疾病中的药物-药物相互作用:临床问题及医学-法律影响。
Int J Environ Res Public Health. 2021 Dec 8;18(24):12936. doi: 10.3390/ijerph182412936.
5
Current Insights into Treating Vertigo in Older Adults.当前针对老年眩晕症的治疗方法。
Drugs Aging. 2021 Aug;38(8):655-670. doi: 10.1007/s40266-021-00877-z. Epub 2021 Jun 23.
6
Cinnarizine: A Contemporary Review.桂利嗪:当代综述。
Indian J Otolaryngol Head Neck Surg. 2019 Nov;71(Suppl 2):1060-1068. doi: 10.1007/s12070-017-1120-7. Epub 2017 Apr 25.
7
Authors' Reply to "The Challenges of Studying Peripheral Vestibular Vertigo".作者对《研究外周性前庭性眩晕的挑战》的回复。
Clin Drug Investig. 2020 Jan;40(1):101-102. doi: 10.1007/s40261-019-00872-8.
8
The Challenges of Studying Peripheral Vestibular Vertigo.研究外周性前庭性眩晕的挑战。
Clin Drug Investig. 2020 Jan;40(1):99-100. doi: 10.1007/s40261-019-00871-9.
9
Management of peripheral vertigo with antihistamines: New options on the horizon.抗组胺药治疗周围性眩晕:新的选择即将出现。
Br J Clin Pharmacol. 2019 Oct;85(10):2255-2263. doi: 10.1111/bcp.14046. Epub 2019 Jul 22.
10
Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice.桂利嗪和茶苯海明在医学实践中治疗眩晕的应用。
Wien Klin Wochenschr. 2016 May;128(9-10):341-7. doi: 10.1007/s00508-015-0905-5. Epub 2015 Dec 11.
倍他司汀治疗可改善单侧前庭损失患者的静态症状恢复。
J Clin Pharmacol. 2011 Apr;51(4):538-48. doi: 10.1177/0091270010369241. Epub 2010 Oct 12.
4
Neuropharmacology of vestibular system disorders.前庭系统障碍的神经药理学。
Curr Neuropharmacol. 2010 Mar;8(1):26-40. doi: 10.2174/157015910790909511.
5
Vestibular function after acute vestibular neuritis.急性前庭神经炎后的前庭功能。
Restor Neurol Neurosci. 2010;28(1):37-46. doi: 10.3233/RNN-2010-0533.
6
Pharmacological modulation of transmitter release by inhibition of pressure-dependent potassium currents in vestibular hair cells.通过抑制前庭毛细胞中压力依赖性钾电流来调节递质释放的药理学调节。
Naunyn Schmiedebergs Arch Pharmacol. 2009 Dec;380(6):531-8. doi: 10.1007/s00210-009-0463-3. Epub 2009 Oct 15.
7
Betahistine in the treatment of Ménière's disease.倍他司汀治疗梅尼埃病。
Neuropsychiatr Dis Treat. 2007 Aug;3(4):429-40.
8
Treatment of vestibular neuritis.前庭神经炎的治疗
Curr Treat Options Neurol. 2009 Jan;11(1):41-5. doi: 10.1007/s11940-009-0006-8.
9
Vestibular neuritis: vertigo and the high-acceleration vestibulo-ocular reflex.前庭神经炎:眩晕与高加速度前庭眼反射
J Neurol. 2008 Oct;255(10):1479-82. doi: 10.1007/s00415-008-0935-2. Epub 2008 Jul 11.
10
Prednisone treatment for vestibular neuritis.泼尼松治疗前庭神经炎。
Otol Neurotol. 2008 Apr;29(3):368-74. doi: 10.1097/MAO.0b013e3181692804.